Research progress on combined immunotherapy with PD-1/PD-L1 inhibitors and anti-VEGF agents in advanced hepatocellular carcinoma
10.12360/CPB202210094
- VernacularTitle:PD-1/PD-L1抑制剂联合抗血管内皮生长因子药物免疫治疗晚期肝癌的研究进展
- Author:
Yan-Ni HUANG
1
;
Xue-Ling LAN
;
Min-Min ZHU
;
Jin-Bin WEI
;
Yan LI
;
Min DONG
Author Information
1. 广西医科大学药学院
- Keywords:
PD-1/PD-L1 inhibitors;
anti-VEGF agents;
combi-nation immunotherapy;
hepatocellular carcinoma;
anti-angiogen-esis;
cancer immunity cycle
- From:
Chinese Pharmacological Bulletin
2024;40(8):1429-1436
- CountryChina
- Language:Chinese
-
Abstract:
Hepatocellular carcinoma(HCC)is one of the most common malignant tumors globally.Programmed death protein-1(PD-1)/programmed death protein ligand-1(PD-L1)inhibitors promote the reactivation of anti-tumor immune response by bloc-king the negative modulatory signaling pathway of T cells'activa-tion and inhibiting the immune escape pathway of tumor cells.PD-1/PD-L1 inhibitors become a novel therapeutic strategy to treat HCC.However,long-term clinical outcomes show that HCC patients treated with anti-PD-1/PD-L1 monotherapy still have high rates of recurrence and metastasis.Combination immuno-therapy is a novel therapeutic strategy to treat advanced HCC pa-tients,among which PD-1/PD-L1 inhibitors in combination with anti-vascular endothelial growth factor(VEGF)agents have showed promising efficacy and better safety.PD-1/PD-L1 inhib-itors plus anti-VEGF agents combined therapy inhibit the growth of hepatoma cells by participating in the cancer immunity cycle pathway.This review focuses on the research progress of PD-1/PD-L1 inhibitors,anti-VEGF agents and their combined therapy in the clinical treatment of HCC.
